Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
781,49 ^USD	-1,48%		-5,59%	+1,25%

10/09	Regeneron Pharmaceuticals : RBC juge probable le maintien du brevet sur l'Eylea HD	MT
09/09	Transcript : Regeneron Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08:45 AM

Autres langues

10/09	MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
10/09	Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
08/09	MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - RGRD Law
04/09	SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
02/09	Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street
02/09	Valores destacados al cierre del mercado norteamericano
01/09	Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says
29/08	Regeneron Pharmaceuticals Inc Initiates Recall of Libtayo (Cemiplimab-Rwlc) Injection, 350 Mg/7 Ml (50 Mg/Ml) For Intravenous Infusion After Dilution, Single-Dose Vial
27/08	AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial
25/08	Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients
20/08	Pasatru (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial
19/08	Regeneron Announces Investor Conference Presentations
19/08	Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition
19/08	US FDA approves Regeneron's rare bone disorder drug
19/08	Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
19/08	Regeneron Pharmaceuticals Announces FDA Approval for Pasatru to Reduce Formation of New Heterotopic Ossification Lesions and Clinician-Assessed Flare-Ups in Adults with Fibrodysplasia Ossificans Progressiva
17/08	EyePoint's drug for age-related eye disease fails late-stage trial, shares tank
03/08	Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
31/07	Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says
31/07	AbbVie Lowers Outlook to Account for Acquisition, as 2Q Profit Jumps
31/07	Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on August 31, 2026
31/07	Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
30/07	Regeneron Pharmaceuticals Shares Rise After Higher Q2 Results
30/07	Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline
30/07	Afternoon Meeting: La inflación da un respiro a la Fed